Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free AGMB Stock Alerts

AgomAb Therapeutics (AGMB) Financials

AgomAb Therapeutics logo
$11.88 -0.10 (-0.83%)
As of 12:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for AgomAb Therapeutics

Annual Income Statements for AgomAb Therapeutics

This table shows AgomAb Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -48 -73
Consolidated Net Income / (Loss)		 -13 -48 -73
Net Income / (Loss) Continuing Operations		 -13 -48 -73
Total Pre-Tax Income 		-13 -48 -73
Total Operating Income		 -35 -50 -70
Total Gross Profit		 1.35 1.47 2.81
Total Revenue		 1.35 1.47 2.81
Operating Revenue		 1.35 1.47 2.81
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 36 51 72
Selling, General & Admin Expense		 6.74 10 15
Research & Development Expense		 29 41 57
Total Other Income / (Expense), net		 21 1.82 -3.84
Interest Expense		 0.10 0.37 0.16
Interest & Investment Income		 0.34 1.31 2.02
Other Income / (Expense), net		 21 0.88 -5.70
Income Tax Expense		 -0.68 0.00 0.00
Weighted Average Basic Shares Outstanding		 -39.41 -110.85 -168.08
Diluted Earnings per Share		 ($39.41) ($110.85) ($168.08)
Weighted Average Diluted Shares Outstanding		 541.13K 541.13K 34.17M
Weighted Average Basic & Diluted Shares Outstanding		 1.08M 1.08M 1.08M

Quarterly Income Statements for AgomAb Therapeutics

No quarterly income statements for AgomAb Therapeutics are available.

Annual Cash Flow Statements for AgomAb Therapeutics

This table details how cash moves in and out of AgomAb Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 105 51 -100
Net Cash From Operating Activities		 37 -49 -61
Net Cash From Continuing Operating Activities		 37 -49 -65
Net Income / (Loss) Continuing Operations		 -13 -48 -73
Consolidated Net Income / (Loss)		 -13 -48 -73
Depreciation Expense		 0.11 0.32 0.26
Non-Cash Adjustments To Reconcile Net Income		 46 -0.14 6.35
Changes in Operating Assets and Liabilities, net		 3.87 -1.32 1.85
Net Cash From Investing Activities		 0.00 -0.70 -39
Net Cash From Continuing Investing Activities		 0.00 -0.70 0.00
Net Cash From Financing Activities		 88 100 -0.40
Net Cash From Continuing Financing Activities		 88 100 -0.40
Repayment of Debt		 - - -0.40
Other Financing Activities, net		 0.00 0.00 0.00

Quarterly Cash Flow Statements for AgomAb Therapeutics

No quarterly cash flow statements for AgomAb Therapeutics are available.

Annual Balance Sheets for AgomAb Therapeutics

This table presents AgomAb Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 214 180
Total Current Assets		 180 107
Cash & Equivalents		 177 101
Other Current Assets		 2.47 5.54
Plant, Property, & Equipment, net		 0.64 0.59
Plant, Property & Equipment, gross		 0.64 0.59
Total Noncurrent Assets		 33 73
Long-Term Investments		 0.00 35
Goodwill		 8.91 10
Intangible Assets		 21 24
Other Noncurrent Operating Assets		 3.28 3.81
Total Liabilities & Shareholders' Equity		 214 180
Total Liabilities		 19 27
Total Current Liabilities		 9.45 22
Accounts Payable		 8.33 12
Accrued Expenses		 0.83 1.82
Other Current Liabilities		 0.28 7.95
Total Noncurrent Liabilities		 9.47 4.95
Capital Lease Obligations		 1.32 1.18
Other Noncurrent Operating Liabilities		 8.16 3.77
Total Equity & Noncontrolling Interests		 195 154
Total Preferred & Common Equity		 195 154
Total Common Equity		 195 154
Common Stock		 231 262
Retained Earnings		 -123 -213
Other Equity Adjustments		 87 105

Quarterly Balance Sheets for AgomAb Therapeutics

No quarterly balance sheets for AgomAb Therapeutics are available.

Annual Metrics And Ratios for AgomAb Therapeutics

This table displays calculated financial ratios and metrics derived from AgomAb Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 34,167,168.00
DEI Adjusted Shares Outstanding		 0.00 0.00 34,167,168.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -2.15
Growth Metrics		 - - -
Revenue Growth		 0.00% 9.24% 90.80%
EBITDA Growth		 0.00% -261.59% -54.63%
EBIT Growth		 0.00% -261.04% -54.14%
NOPAT Growth		 0.00% -44.07% -39.95%
Net Income Growth		 0.00% -280.10% -53.28%
EPS Growth		 0.00% -181.24% -51.63%
Operating Cash Flow Growth		 0.00% -231.89% -23.86%
Free Cash Flow Firm Growth		 0.00% 0.00% 9.52%
Invested Capital Growth		 0.00% 0.00% -2.47%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 100.00%
EBITDA Margin		 -995.65% -3,295.50% -2,670.83%
Operating Margin		 -2,560.75% -3,377.00% -2,477.02%
EBIT Margin		 -1,003.78% -3,317.37% -2,679.98%
Profit (Net Income) Margin		 -935.14% -3,253.66% -2,613.75%
Tax Burden Percent		 94.85% 100.01% 100.00%
Interest Burden Percent		 98.23% 98.07% 97.53%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -375.71% -266.19%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -360.84% -250.33%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 326.51% 224.04%
Return on Equity (ROE)		 0.00% -49.20% -42.15%
Cash Return on Invested Capital (CROIC)		 0.00% -575.71% -263.69%
Operating Return on Assets (OROA)		 0.00% -22.86% -38.21%
Return on Assets (ROA)		 0.00% -22.42% -37.26%
Return on Common Equity (ROCE)		 0.00% -49.20% -42.15%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -24 -35 -49
NOPAT Margin		 -1,792.53% -2,363.90% -1,733.91%
Net Nonoperating Expense Percent (NNEP)		 0.00% -14.87% -15.85%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.75% -31.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 500.57% 712.59% 534.52%
R&D to Revenue		 2,160.18% 2,764.42% 2,042.50%
Operating Expenses to Revenue		 2,660.75% 3,477.00% 2,577.02%
Earnings before Interest and Taxes (EBIT)		 -14 -49 -75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -49 -75
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 1.03 1.30
Price to Tangible Book Value (P/TBV)		 0.00 1.21 1.67
Price to Revenue (P/Rev)		 148.44 135.88 71.21
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.29 3.57
Enterprise Value to Revenue (EV/Rev)		 0.00 16.20 22.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.01 0.01
Long-Term Debt to Equity		 0.00 0.01 0.01
Financial Leverage		 0.00 -0.90 -0.90
Leverage Ratio		 0.00 1.10 1.13
Compound Leverage Factor		 0.00 1.08 1.10
Debt to Total Capital		 0.00% 0.67% 0.76%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.67% 0.76%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.33% 99.24%
Debt to EBITDA		 0.00 -0.03 -0.02
Net Debt to EBITDA		 0.00 3.63 1.81
Long-Term Debt to EBITDA		 0.00 -0.03 -0.02
Debt to NOPAT		 0.00 -0.04 -0.02
Net Debt to NOPAT		 0.00 5.06 2.78
Long-Term Debt to NOPAT		 0.00 -0.04 -0.02
Altman Z-Score		 0.00 5.74 2.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.00 19.05 4.90
Quick Ratio		 0.00 18.79 4.65
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -53 -48
Operating Cash Flow to CapEx		 0.00% -7,017.03% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -144.28 -309.05
Operating Cash Flow to Interest Expense		 390.73 -132.68 -389.03
Operating Cash Flow Less CapEx to Interest Expense		 390.73 -134.57 -389.03
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 2.30 4.56
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 19 18
Invested Capital Turnover		 0.00 0.16 0.15
Increase / (Decrease) in Invested Capital		 0.00 19 -0.46
Enterprise Value (EV)		 0.00 24 64
Market Capitalization		 200 200 200
Book Value per Share		 $0.00 $359.77 $4.50
Tangible Book Value per Share		 $0.00 $304.83 $3.51
Total Capital		 0.00 196 155
Total Debt		 0.00 1.32 1.18
Total Long-Term Debt		 0.00 1.32 1.18
Net Debt		 0.00 -176 -136
Capital Expenditures (CapEx)		 0.00 0.70 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -6.98 -16
Debt-free Net Working Capital (DFNWC)		 0.00 171 85
Net Working Capital (NWC)		 0.00 171 85
Net Nonoperating Expense (NNE)		 -12 13 25
Net Nonoperating Obligations (NNO)		 0.00 -176 -136
Total Depreciation and Amortization (D&A)		 0.11 0.32 0.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -473.98% -579.44%
Debt-free Net Working Capital to Revenue		 0.00% 11,583.62% 3,031.84%
Net Working Capital to Revenue		 0.00% 11,583.62% 3,031.84%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 -168.00
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($168.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 34.17M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -35 -49
Normalized NOPAT Margin		 -1,792.53% -2,363.90% -1,733.91%
Pre Tax Income Margin		 -985.96% -3,253.38% -2,613.75%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -142.16 -132.14 -482.19
NOPAT to Interest Expense		 -253.87 -94.16 -311.97
EBIT Less CapEx to Interest Expense		 -142.16 -134.03 -482.19
NOPAT Less CapEx to Interest Expense		 -253.87 -96.05 -311.97
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AgomAb Therapeutics

No quarterly metrics and ratios for AgomAb Therapeutics are available.


Financials Breakdown Chart

AgomAb Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AgomAb Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

AgomAb Therapeutics' net income appears to be on an upward trend, with a most recent value of -$73.41 million in 2025, rising from -$12.60 million in 2023. The previous period was -$47.89 million in 2024. View AgomAb Therapeutics' forecast to see where analysts expect AgomAb Therapeutics to go next.

AgomAb Therapeutics' total operating income in 2025 was -$69.57 million, based on the following breakdown:
  • Total Gross Profit: $2.81 million
  • Total Operating Expenses: $72.37 million

Over the last 2 years, AgomAb Therapeutics' total revenue changed from $1.35 million in 2023 to $2.81 million in 2025, a change of 108.4%.

AgomAb Therapeutics' total liabilities were at $26.76 million at the end of 2025, a 41.5% increase from 2024, and a 41.5% increase since 2024.

In the past 1 years, AgomAb Therapeutics' cash and equivalents has ranged from $101.42 million in 2025 to $177.48 million in 2024, and is currently $101.42 million as of their latest financial filing in 2025.

Over the last 2 years, AgomAb Therapeutics' book value per share changed from 0.00 in 2023 to 4.50 in 2025, a change of 449.6%.


Related Companies

Financial statements for NASDAQ:AGMB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel